Cancer immunotherapy

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 14, 2023
Annual general meeting, Bone marrow, Phenotype, ASH, Patient, Cell, Research, NF, Marketing, Therapy, CMS, Diagnosis, Safety, Rituximab, Myelocyte, SITC, CD20, ATM, Kinetics, UCLA Health, Society, Health, Courage, Corporation, Pivotal, UCB, Fibroblast, Whole blood, Immune reconstitution inflammatory syndrome, Partnership, NAM, Ronald Reagan, Medicare, Policy, FDA, Immunotherapy, Survival, Toxic epidermal necrolysis, Cancer immunotherapy, Lymphoma, Mesa, Video game, Pharmaceutical industry, Dentistry, Vaccine, Mobile phone, Transplant, NK

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.
  • “The third quarter marked the first patients receiving Omisirge following FDA approval and the point at which Gamida Cell truly transitioned to a commercial-stage company with our first revenue reported,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • The company reported revenue for the delivery of two units of Omisirge in the third quarter of 2023 and projects revenue from a total of four to six units for full year 2023.
  • Annual shareholders meeting: Gamida Cell held its Annual General Meeting of Shareholders in New York City on October 19.

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023
MDSC, Consultant, Associate, Cancer immunotherapy, CD16, Therapy, Society for Immunotherapy of Cancer, Prostate cancer, MD, University, Myeloid-derived suppressor cell, GT, Doctor of Philosophy, Cell, Prostate, SITC, Immunotherapy, NK, Annual general meeting, PCA, Tumor microenvironment, Society, TME, PSMA, Hypoxia, Trike, Vaccine, Medicine

Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.

Key Points: 
  • Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.
  • However, lack of antigen-specific targeting, decreased numbers, and suppressive signals from the tumor microenvironment (TME) of Prostate Cancer (PCa), can negatively impact NK cell efficacy.
  • The TriKE molecules displayed improved tumor control, compared to IL-15 control or no treatment, in xenogeneic models of prostate cancer.
  • Society For Immunotherapy of Cancer (SITC) 2023 Annual Meeting – November 1-5, 2023

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, Neoplasm, Patient, FRCP, MDSC, PRS, NSCLC, Poster, PD, Aes, UC, Publication, Vomiting, DCR, Diarrhea, Pembrolizumab, Metastasis, Associate professor, Safety, Conference, Doctor of Philosophy, MBBS, Data, Nausea, CD8, Rash, Cancer immunotherapy, Immunotherapy, Rock, SD, DRAGON, SITC, San Diego Convention Center, Biopsy, Annual general meeting, ORR, University, RECIST, Biomarker, Melanoma, Lung cancer, Society, Therapy, AE, Carcinoma, Spectrochimica Acta Part B, Dermatitis, PR, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging, Nightclub, Part

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects

Retrieved on: 
Saturday, November 4, 2023
Society for Immunotherapy of Cancer, Mitochondrion, Immunogenic cell death, ICD, Bax, Northern blot, Doctor of Philosophy, Phosphorylation, Bcl-2, SITC, Cancer immunotherapy, Immunotherapy, Reactive oxygen species, ISR, Research and development, Cancer, Flow cytometry, Annual general meeting, Weill Cornell Medicine, Lung cancer, Endoplasmic reticulum, Society, Therapy, Patient, Cytosol, DNA, Vaccine, Platinum, Research

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death (ICD) in cancer cells. Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.

Key Points: 
  • Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism.
  • The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
  • PT-112 effects on mitochondria included increases in mitochondrial mass and reactive oxygen species, changes in membrane polarization, and the release of mitochondrial DNA into the cytosol, a potent immunogenic signal.
  • For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .

Promontory Therapeutics to Present Data on PT-112 Mechanism of Action at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Retrieved on: 
Thursday, October 26, 2023
Society for Immunotherapy of Cancer, Lung cancer, Cancer immunotherapy, Immunotherapy, SITC, Society, Therapy, Annual general meeting, Medical imaging

NEW YORK, Oct. 26, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, will present a poster demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. SITC is taking place November 1-5, 2023 in San Diego.

Key Points: 
  • NEW YORK, Oct. 26, 2023 /PRNewswire/ -- Promontory Therapeutics Inc. , a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, will present a poster demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting.
  • SITC is taking place November 1-5, 2023 in San Diego.
  • PT-112 is the subject of ongoing Phase 2 clinical trials for metastatic castrate-resistant prostate cancer and thymic epithelial tumors, and a completed Phase 2a trial in non-small cell lung cancer.
  • For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .

Montefiore Einstein Cancer Center Awarded $2.9M NCI Calabresi Training Award

Retrieved on: 
Wednesday, June 7, 2023
Black Hours, Hispanic Society, New York, Translation, Albert Einstein, Calabresi, MECC, Curriculum, Pathology, Health equity, Research, Bangladesh Technical Education Board, Cancer immunotherapy, National Cancer Institute, Cancer, Patient, Montefiore Medical Center, Physician, Translational research, Albert Einstein College of Medicine, Faculty, Knowledge, NCI, Breast cancer, Pharmaceutical industry, Nursing, Black, Montefiore

BRONX, N.Y., June 7, 2023 /PRNewswire/ -- The National Cancer Institute (NCI)-designated Montefiore Einstein Cancer Center (MECC) has received a five-year, $2.9 million grant from the NCI to train physicians and scientists to conduct clinical and translational oncology research, with a special emphasis on investigating and addressing health inequities in the Bronx. The funding, part of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO), will support up to four scholars for two to three years.

Key Points: 
  • The funding, part of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO), will support up to four scholars for two to three years.
  • MECC provides a unique opportunity for scholars interested in training at an NCI-designated cancer center and conducting research with patients from historically marginalized communities.
  • , co-director of the Cancer Therapeutics program and director of the Cancer Immunotherapy program at MECC, and associate professor of oncology, of microbiology & immunology, and of pathology at Einstein.
  • The title of the grant is "Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx."

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Retrieved on: 
Monday, February 27, 2023
MD Anderson Cancer Center, Cancer, MD, UCSF Helen Diller Family Comprehensive Cancer Center, KOL, UCSF, Associate, University, Biomarker, Research, University of California, FDA, Patient, Adenosine, Immunosuppression, Cancer immunotherapy, Division, Tumor microenvironment, PRTG, Vaccine, Pharmaceutical industry

WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it will host a key opinion leader (KOL) webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at 10:30 am Eastern Time.

Key Points: 
  • A critical mechanism of cancer immune evasion is the generation of high levels of immunosuppressive adenosine within the tumor microenvironment.
  • Portage’s virtual KOL event will discuss what can be learned from agents that target adenosine for the treatment of cancer, and how Portage plans to augment an immune response with its next-generation small molecule adenosine 2A and adenosine 2B inhibitors.
  • Lawrence Fong, M.D., is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at UCSF.
  • He also co-directs the Parker Institute for Cancer Immunotherapy at UCSF and co-leads the Cancer Immunology Program in the Helen Diller Family Comprehensive Cancer Center.

Global Therapeutic Monoclonal Antibodies Market Report 2022: North America Leads the Way with Significant Growth Expected in Europe and Asia Pacific - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Health, Biotechnology, Research report, USD, Cell, Degenerative disease, Administration, Cancer immunotherapy, MEA, Growth, Route of administration, Infection, United Kingdom, Prevalence, Conditional sentence, Targets, Humanized antibody, Incidence, Intravenous therapy, Generic drug, Vaccine, Target, Cancer

According to the research report, the Therapeutic Monoclonal Antibodies Market is projected to display significant growth represented by a CAGR of 18.63% during 2022-2028.

Key Points: 
  • According to the research report, the Therapeutic Monoclonal Antibodies Market is projected to display significant growth represented by a CAGR of 18.63% during 2022-2028.
  • America is the largest market for Therapeutic Monoclonal Antibodies with the U.S. accounting for a major share of the total Therapeutic Monoclonal Antibodies consumption in the region.
  • The report analyses the Therapeutic Monoclonal Antibodies By Source (Humanized, Murine, Chimeric, Human)
    The report analyses the Therapeutic Monoclonal Antibodies Market, By Target (Cell surface antigen, plasma protein or drug, Other Targets, infectious organism)
    The report analyses the Therapeutic Monoclonal Antibodies Market by Indication (Cancer, Infectious Disease, Autoimmune Disorders, Neurological Disorders, Other Indications).
  • The Global Therapeutic Monoclonal Antibodies Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Todos Medical Announces Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022
CFO, CBN, Risk, EUA, Brain, Legislation, COVID-19 policy of the Joe Biden administration, Apoptosis, Dietary supplement, TMB-2, Synthase, Severe acute respiratory syndrome coronavirus 2, Neuron, Immune system, B cell, Patient, COVID, Lymphocyte, Trial of the century, Pressure, Plasma, COVID-19, Cancer immunotherapy, Public health, Cancer, Physician, Neurodegeneration, Monocyte, Amazon, IRB, TBIA, Alzheimer's disease, Research, OTCQB, Cell cycle, Knowledge, Biotechnology, Aerospace, CLIA, PCR, CBG, Memory, Emergency Use Authorization, Diagnosis, Natural killer T cell, Pharmaceutical industry, Vaccine, Video game, Medical imaging, Long COVID, CBD, Pharma

New York, NY, and Tel Aviv, ISRAEL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the third quarter of 2022, which ended on September 30, 2022. The Company will host a conference call today at 8:30am ET on November 15, 2022.

Key Points: 
  • In the second quarter of 2022, 3CL Pharma announced positive biomarker data stemming from a positive clinical Phase 2 clinical study initially reported in January 2022.
  • In the second quarter of 2022, the Company received an IRB waiver to conduct a market research study on customer experience using Tollovid.
  • Revenues: Total revenue in the third quarter of 2022 was$1.914 million, as compared to revenue of $1,010,000in the third quarter of 2021.
  • Loss from Operations: The Company recorded an operating loss of$(1,802,000)in the third quarter of 2022 compared to an operating loss of$(2,497,000)in the third quarter of 2021.